• GlycoRNA–RBP Domains and TAT Cell Entry

  2026-10-07

  A 2023 bioRxiv preprint reports that cell-surface RNA-binding proteins and glycoRNAs organize into nanoclusters that support entry of the cell-penetrating peptide TAT. The study broadens the conventional view of the plasma membrane, while its preprint status and unresolved questions about molecular specificity limit how far the findings can currently be generalized.

• D2-Like Dopamine Signaling in PPT1KI Mice

  2026-10-07

  A 2025 study links PPT1 deficiency in PPT1KI mice to altered dopamine receptor profiles, impaired hippocampal gamma oscillations, and cognitive dysfunction. Its pharmacological findings suggest that D2-like receptor signaling, particularly through DR4, may be a modifiable network-level pathway, although the evidence remains preclinical and does not establish a disease-modifying treatment.

• SGI-1027: DNA Methyltransferase Inhibitor Evidence

  2026-10-06

  SGI-1027 is a non-nucleoside DNA methyltransferase inhibitor studied as an epigenetic modulator for cancer research. In Huh7 hepatocellular carcinoma cells, a peer-reviewed study associated SGI-1027 exposure with reduced viability and apoptosis, but the evidence remains limited to an in-vitro model.

• Trichostatin A and the Translational Epigenetics Gap

  2026-10-06

  Trichostatin A (TSA) is more than a benchmark HDAC inhibitor: it is a mechanistic probe for testing how chromatin state intersects with tumor-cell plasticity, combination response, and translational biomarker strategy.

• Sulfo-NHS-LC-Biotin Product Overview

  2026-10-05

  Sulfo-NHS-LC-Biotin, also known as sulfosuccinimidyl-6-(biotinamido) hexanoate, is documented by APExBIO as a water-soluble reagent for covalent labeling of accessible primary amines on proteins and peptides. No matched paper evidence was supplied, so performance and application claims remain unvalidated here.

• GlycoRNA–RBP Surface Domains and Peptide Entry

  2026-10-05

  A 2023 bioRxiv preprint reports that extracellular RNA-binding proteins and glycoRNAs organize into cell-surface nanoclusters associated with TAT peptide entry. The findings expand the conventional view of the plasma membrane while highlighting important questions about molecular topology, causality, and how broadly the mechanism applies.

• Sulfo-NHS-LC-Biotin Product Overview

  2026-10-04

  Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-(biotinamido) hexanoate; SKU A8003) is described by APExBIO as a water-soluble reagent for covalent biotin labeling of accessible primary amines. No matched paper evidence was supplied, so this overview addresses product identity and stated conceptual scope only.

• Decitabine: Interpreting Epigenetic Toxicology Evidence

  2026-10-03

  Decitabine and 5-Aza-2'-deoxycytidine connect DNA methylation biology with measurable toxicity and therapeutic response. This evidence-led guide explains what the foundational mouse study demonstrates, where its conclusions stop, and how to interpret the compound in cancer epigenetics research.

• Liposomal Ce6 PDT Drives Pyroptosis in Breast Cancer

  2026-10-01

  The reference study shows that liposomal chlorin e6 photodynamic therapy can convert mitochondrial oxidative damage into caspase-1-associated pyroptosis and immunogenic cell death in breast cancer models. Its combination with an immune checkpoint inhibitor further improved tumor control, highlighting a mechanistic basis for integrating PDT with cancer immunotherapy while leaving formulation, irradiation, and clinical translation questions open.

• Sulfo-NHS-SS-Biotin for Cell-Surface Proteomics

  2026-10-01

  Sulfo-NHS-SS-Biotin combines water-soluble amine reactivity with a cleavable disulfide linker for topology-aware protein labeling. This guide explains how to use the K1006 kit to interpret cell-surface proteomics and investigate RNA-associated surface domains without overstating what biotinylation alone can prove.

• Sulfo-Cy3 NHS Ester for Vascular Uptake Assays

  2026-09-30

  Sulfo-Cy3 NHS Ester combines aqueous compatibility with bright orange-red fluorescence for tracking protein uptake, endothelial remodeling, and biomolecular interactions. This guide translates the AIBP–LRP2 vascular mechanism into practical labeling, imaging, controls, and troubleshooting workflows.

• EZ Cap™ OVA mRNA for Immune Research

  2026-09-30

  EZ Cap™ OVA mRNA provides a defined Ovalbumin mRNA payload for immune response immunogen studies, gene expression studies, and vaccine development research. Its Cap 1 structure and poly(A) tail support practical delivery comparisons, including emerging low-inflammation lipid nanoparticle workflows.

• Sulfo-Cy5 NHS Ester in Cell Assays

  2026-09-29

  Learn how Sulfo-Cy5 NHS ester (SKU A8108) supports aqueous protein labeling, far-red cellular imaging, and more interpretable viability or cytotoxicity workflows. This scenario-based guide connects reagent chemistry, storage, controls, and vendor evaluation to practical laboratory decisions.

• Biotin-HPDP: From Thiols to Translation

  2026-09-29

  A thought-leadership guide to using Biotin-HPDP as a reversible thiol-labeling tool in translational redox biology, with a mechanistic bridge to PPT1-linked neurodegeneration, dopamine receptor biology, affinity workflows, and preclinical assay strategy.

• Wnt agonist 1: Workflows for Mechanistic Research

  2026-09-28

  Wnt agonist 1 (BML-284) provides a titratable way to probe β-catenin–TCF signaling in differentiation, development, and cancer models. This practical workflow connects pathway activation with the Wnt/NR2F2/GPX4 chemoresistance axis while separating validated evidence from experimental recommendations.

8618 records 1/575 page Next 12345 下5页 Last page